# IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer

> **NCT04434482** · PHASE1,PHASE2 · COMPLETED · sponsor: **Impact Therapeutics, Inc.** · enrollment: 59 (actual)

## Conditions studied

- Advanced Solid Tumours
- Small Cell Lung Cancer

## Interventions

- **DRUG:** IMP4297(senaparib)

## Key facts

- **NCT ID:** NCT04434482
- **Lead sponsor:** Impact Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-07
- **Primary completion:** 2024-04-29
- **Final completion:** 2024-04-29
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04434482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04434482, "IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04434482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*